MediBeacon expands management team as
enrollment in Phase 3 study focused on kidney disease is
completed
ST.
LOUIS, May 16, 2023 /CNW/ -- MediBeacon Inc., a
portfolio company within the Pansend Life Sciences
segment of INNOVATE Corp. (NYSE: VATE), today announced the
appointment of Dr. Steve Miller as
chief medical officer. In this role, Dr. Miller will be focused on
driving a range of clinical and strategic initiatives.
Dr. Miller formerly served as executive vice president and chief
clinical officer at Cigna, where he led the
company's clinical policy, quality, and performance efforts.
Dr. Miller was chief medical officer at Express Scripts in advance
of Cigna's acquisition of the company. Prior to Express Scripts Dr.
Miller was vice president and chief medical officer at
Barnes-Jewish Hospital, Washington
University School of Medicine in St. Louis. He has been a member of the
MediBeacon board of directors since 2015.
"We are thrilled to have Dr. Miller take on a more active role
at MediBeacon," said Steve Hanley,
chief executive officer, MediBeacon. "Dr. Miller has a strong
understanding of the MediBeacon kidney monitoring technology as it
applies to a range of unmet medical needs. His intimate knowledge
of the company, combined with his business, healthcare policy,
medical, clinical and research experience provides unique and
valuable perspective."
MediBeacon is a medical technology company focused on advancing
fluorescent technology to help improve patient care through the
science of tracer agents and transdermal measurement.
"Understanding kidney function remains a significant clinical
challenge," said Dr. Miller. "Real-time, accurate renal function
measurements have the potential to have meaningful impact in
patient management. MediBeacon's goal continues to be to provide
technology to aid in both improving health outcomes and reducing
costs of kidney disease."
Dr. Miller received his medical degree from the University of Missouri-Kansas City and completed an
internal medicine residency at the University
of Colorado. He trained as a fellow in pathology and
research at the University of Alabama,
Birmingham; nephrology at Washington
University; and did a cardiology research fellowship at
University of California, San
Francisco. Dr. Miller earned an MBA at the Washington University Olin Business School.
The MediBeacon® Transdermal GFR Measurement System
(TGFR) is designed to measure Glomerular Filtration Rate (GFR), an
indicator of kidney function, in real-time without the need for
blood sampling or urine collection. The TGFR was designated a
Breakthrough Device by the U.S. FDA and an Innovative Medical
Device by China NMPA.
MediBeacon TGFR Pivotal Study
MediBeacon TGFR Pivotal Study (NCT05425719) is a Phase 3 open
label, multi-center, safety and pharmacokinetic study of
Lumitrace® (relmapirazin) and the use of the MediBeacon
Transdermal GFR Measurement System (TGFR) in normal and renal
compromised subjects for the evaluation of kidney function. The
safety and effectiveness of the MediBeacon TGFR for point of care
non-invasive transdermal fluorescence detection of Lumitrace is
being evaluated in subjects with kidney function from normal to
Stage 4 CKD. Patient enrollment covers the entire range of human
skin colors spanning fair to black pigmentation. The study's
primary outcome measure is the correlation of Transdermal Derived
Glomerular Filtration Rate (tGFR) to the Measured GFR (mGFR)
obtained from blood samples collected over time.1
About
Lumitrace® (relmapirazin)
Lumitrace is an investigational pyrazine-based compound which
has been engineered to be inert, highly fluorescent and have the
clearance properties of a GFR tracer agent in the body. The
investigational Lumitrace solution for injection has been
administered to over 500 subjects under Investigational Device
Exemptions (IDEs). The unique photophysical characteristics of
Lumitrace have been designed to enable the collection of
fluorescence data via a photodetector sensor placed on the skin.
Data collected by the sensor measures the change in the intensity
of Lumitrace fluorescence over time and is converted into a tGFR by
proprietary algorithms.
About MediBeacon Inc.
MediBeacon is a medical technology company specializing in the
advancement of fluorescent tracer agents and transdermal detection.
MediBeacon's use of proprietary fluorescent tracer agents coupled
with transdermal detection technology focuses on providing vital
and actionable measurement of organ function. MediBeacon's 47
granted U.S. patents and 170+ granted patents worldwide provide
extensive coverage of the MediBeacon TGFR, including Lumitrace, the
sensor and algorithms, as well as other strategic uses of its
proprietary pyrazine platform and sensor technology including
potential applications in nephrology, gastroenterology,
ophthalmology and surgery. MediBeacon products are in various
stages of clinical development and are NOT yet approved for human
use. For more information, please visit: www.medibeacon.com
About INNOVATE Corp.
INNOVATE Corp. is a portfolio of best-in-class assets in three
key areas of the new economy – Infrastructure, Life Sciences and
Spectrum. Dedicated to stakeholder capitalism, INNOVATE employs
approximately 3,900 people across its subsidiaries. For more
information, please visit: www.INNOVATECorp.com.
1 ClinicalTrials.gov
View original content to download
multimedia:https://www.prnewswire.com/news-releases/medibeacon-inc-appoints-dr-steve-miller-as-chief-medical-officer-301825436.html
SOURCE MediBeacon Inc.